Patent US5510418A successfully refreshed from Google Patents.
US5510418A
Expired / Lapsed
US
⏱️ 0.0 years remaining
Glycosaminoglycan-synthetic polymer conjugates
Assignee: Surgical Specialties US Corp
•
Filing: 1993-11-03
•
Granted: 1996-04-23
•
Expires: 2013-11-03
Abstract
Abstract Pharmaceutically acceptable, nonimmunogenic compositions are formed by covalently binding glycosaminoglycans or derivatives thereof, to hydrophilic synthetic polymers via specific types of chemical bonds to provide biocompatible conjugates. Useful glycosaminoglycans include hyaluronic acid, the chondroitin sulfates, keratan sulfate, chitin and heparin, each of which is chemically derivatized to react with a hydrophilic synthetic polymer. The conjugate comprising a glycosaminoglycan covalently bound to a hydrophilic synthetic polymer may be further bound to collagen to form a three component conjugate having different properties. The hydrophilic synthetic polymer may be polyethylene glycol and derivatives thereof having an average molecular weight over a range of from about 100 to about 100,000. The compositions may include other components such as fluid, pharmaceutically acceptable carriers to form injectable formulations, and/or biologically active proteins such as growth factors or cytokines. The conjugates of the invention generally contain large amounts of water when formed. The conjugates can be dehydrated to form a relatively solid implant for use in hard tissue augmentation. The dehydrated, solid implant can further be ground into particles which can be suspended in a non-aqueous fluid and injected into a living being (preferably human) for soft tissue augmentation. Once in place, the solid implants or particles rehydrate and expand in size approximately three- to five-fold.
Inventors
- 👤 Woonza M. Rhee
- 👤 Richard A. Berg
Bibliographic Details
Application Number
—
Jurisdiction
US
Data Source
google_patents
Last Synchronized
2026-10-23 11:56
CPC Classifications
C; C08; C08L; C08L89/00; C08L89/04; C08L89/06; A; A61; A61K; A61K47/00; A61K47/50; A61K47/51; A61K47/56; A61K47/59; A61K47/60; A61K47/61; A61K47/62; A61K47/64; A61K47/6435; A61L; A61L24/00; A61L24/04; A61L24/10; A61L24/102; A61L26/00; A61L26/0009; A61L26/0028; A61L26/0033; A61L27/00; A61L27/14; A61L27/18; A61L27/20; A61L27/22; A61L27/24; A61L27/26; A61L27/28; A61L27/34; A61L27/40; A61L27/44; A61L27/50; A61L27/54; A61L29/00; A61L29/04; A61L29/043; A61L29/044; A61L29/045; A61L29/06; A61L29/14; A61L29/16; A61L31/00; A61L31/04; A61L31/041; A61L31/042; A61L31/043; A61L31/044; A61L31/08; A61L31/10; A61L31/12; A61L31/125; C07; C07K; C07K14/00; C07K14/435; C07K14/475; C07K14/495; C07K14/78; C08B; C08B37/00; C08B37/006; C08B37/0063; C08B37/0069; C08B37/0072; C08H; C08H1/00; C08H1/06; C09; C09J; C09J189/00; C09J189/04; C09J189/06; A61F; A61F2/00; A61F2/02; A61F2/04; A61F2/06; A61F2/07; A61F2310/00; A61F2310/00005; A61F2310/00365; A61K38/00; A61L2300/00; A61L2300/20; A61L2300/23; A61L2300/236; A61L2300/252; A61L2300/40; A61L2300/412; A61L2300/414; A61L2300/80; A61L2300/802; A61L2430/00; A61L2430/16; C08L2666/00; C08L2666/02; Y; Y10; Y10S; Y10S525/00; Y10S525/937
Claims Analysis
Total Claims: 34
Claim 1
Independent Claim
17 words
A biocompatible, biologically inert conjugate comprising a chemically derivatized glycosaminoglycan chemically conjugated to a synthetic hydrophilic polymer.
Claim 2
Dependent Claim
17 words
A biocompatible, biologically inert conjugate comprising a chemically derivatized glycosaminoglycan chemically conjugated to a synthetic hydrophilic polymer.
Claim 3
Dependent Claim
43 words
The conjugate of claim 1, wherein the chemically derivatized glycosaminoglycan is selected from the group consisting of derivatives of the following glycosaminoglyc ans: hyaluronic acid, chondroitin sulfate A, chondroitin sulfate C, dermatan sulfate, heparin, keratan sulfate, keratosulfate, chitin, chitosan 1, and chitosan 2.
Claim 4
Dependent Claim
14 words
The conjugate of claim 1, wherein the glycosaminoglycan is derivatized by deacetylation or desulfation.
Claim 5
Dependent Claim
16 words
The conjugate of claim 1, wherein the synthetic hydrophilic polymer is a multifunctionally activated polyethylene glycol.
Claim 6
Dependent Claim
16 words
The conjugate of claim 4, wherein the synthetic hydrophilic polymer is a difunctionally activated polyethylene glycol.
Claim 7
Dependent Claim
40 words
The conjugate of claim 1, wherein the conjugate has the following general structural formula: GAG-HN-OC-(CH.sub.2).sub.n -Z-PEG-Z-(CH.sub.2).sub.n -CO-NH-GAG wherein n is an integer ranging from 0 to about 4, GAG is a chemically derivatized glycosaminoglycan, and Z is O or O--C═O.
Claim 8
Dependent Claim
49 words
The conjugate of claim 1, wherein the conjugate has the following general structural formula: GAG-HN-OC-(CH.sub.2).sub.n -Z-PEG-Z-(CH.sub.2).sub.n -CO-NH-GAG' wherein n is an integer ranging from 0 to about 4, GAG is a chemically derivatized glycosaminoglycan, GAG' is a different species of chemically derivatized glycosaminoglycan, and Z is O or O--C═O.
Claim 9
Dependent Claim
44 words
The conjugate of claim 6 or claim 7, wherein GAG and GAG' are selected from the group consisting of derivatives of the following glycosaminoglycans: hyaluronic acid, chondroitin sulfate A, chondroitin sulfate C, dermatan sulfate, heparin, keratan sulfate, keratosulfate, chitin, chitosan 1, and chitosan 2.
Claim 10
Dependent Claim
26 words
The conjugate of claim 1, in the form of a hydrogel composition having a moisture content in the range of from about 5% to about 95%.
Claim 11
Dependent Claim
38 words
An injectable, pharmaceutically acceptable composition comprising: a conjugate comprised of a glycosaminoglycan or a derivative thereof chemically conjugated to a hydrophilic synthetic polymer; and a sufficient amount of a fluid pharmaceutically acceptable carder to render the composition injectable.
Claim 12
Dependent Claim
38 words
An injectable, pharmaceutically acceptable composition comprising: a conjugate comprised of a glycosaminoglycan or a derivative thereof chemically conjugated to a hydrophilic synthetic polymer; and a sufficient amount of a fluid pharmaceutically acceptable carder to render the composition injectable.
Claim 13
Dependent Claim
45 words
The composition of claim 10, wherein the glycosaminoglycan is selected from the group consisting of hyaluronic acid, chondroitin sulfate A, chondroitin sulfate C, dermatan sulfate, heparin, keratan sulfate, keratosulfate, chitin, chitosan 1, chitosan 2, and derivatives thereof, and mixtures of these glycosaminoglycans or their derivatives.
Claim 14
Dependent Claim
29 words
A compositon suitable for coating an implant, comprising a conjugate including a difunctionally activate hydrophilic synthetic polymer chemically conjugated to at least one species of glycosaminoglycan or derivative thereof.
Claim 15
Dependent Claim
29 words
A compositon suitable for coating an implant, comprising a conjugate including a difunctionally activate hydrophilic synthetic polymer chemically conjugated to at least one species of glycosaminoglycan or derivative thereof.
Claim 16
Dependent Claim
33 words
The composition of claim 12, wherein the conjugate comprises a difunctionally activated hydrophilic synthetic polymer chemically conjugated to one species of glycosaminoglycan or a derivative thereof, and to collagen or a derivative thereof.
Claim 17
Dependent Claim
26 words
The composition of claim 12, wherein the conjugate comprises a difunctionally activated hydrophilic synthetic polymer chemically conjugated to two different species of glycosaminoglycans or derivatives thereof.
Claim 18
Dependent Claim
26 words
The composition of claim 12, wherein the conjugate comprises a difunctionally activated hydrophilic synthetic polymer chemically conjugated to one species of glycosaminoglycan or a derivative thereof.
Claim 19
Dependent Claim
45 words
The composition of claim 12, wherein the glycosaminoglycan is selected from the group consisting of hyaluronic acid, chondroitin sulfate A, chondroitin sulfate C, dermatan sulfate, heparin, keratan sulfate, keratosulfate, chitin, chitosan 1, chitosan 2, and derivatives thereof, and mixtures of these glycosaminoglycans or their derivatives.
Claim 20
Dependent Claim
20 words
The composition of claim 13, wherein the collagen is selected from the group consisting of fibrillar collagen and nonfibrillar collagen.
Claim 21
Dependent Claim
48 words
A composition suitable for augmentation of hard tissue in a mammal, comprising a biocompatible, biologically inert conjugate comprising a difunctionally activated hydrophilic synthetic polymer chemically conjugated to at least one species of glycosaminoglycan or derivative thereof, wherein the conjugate has been dehydrated to remove substantially all unbound water.
Claim 22
Dependent Claim
48 words
A composition suitable for augmentation of hard tissue in a mammal, comprising a biocompatible, biologically inert conjugate comprising a difunctionally activated hydrophilic synthetic polymer chemically conjugated to at least one species of glycosaminoglycan or derivative thereof, wherein the conjugate has been dehydrated to remove substantially all unbound water.
Claim 23
Dependent Claim
33 words
The composition of claim 18, wherein the conjugate comprises a difunctionally activated hydrophilic synthetic polymer chemically conjugated to one species of glycosaminoglycan or a derivative thereof, and to collagen or a derivative thereof.
Claim 24
Dependent Claim
26 words
The composition of claim 18, wherein the conjugate comprises a difunctionally activated hydrophilic synthetic polymer chemically conjugated to two different species of glycosaminoglycans or derivatives thereof.
Claim 25
Dependent Claim
26 words
The composition of claim 18, wherein the conjugate comprises a difunctionally activated hydrophilic synthetic polymer chemically conjugated to one species of glycosaminoglycan or a derivative thereof.
Claim 26
Dependent Claim
42 words
The composition of claim 18, wherein the glycosaminoglycans are covalently bound to the hydrophilic synthetic polymer via a linkage selected from the group consisting of an ester linkage, an ether linkage, a urethane linkage, and a --(CH 2 ) n --NH-- linkage.
Claim 27
Dependent Claim
45 words
The composition of claim 18, wherein the glycosaminoglycan is selected from the group consisting of hyaluronic acid, chondroitin sulfate A, chondroitin sulfate C, dermatan sulfate, heparin, keratan sulfate, keratosulfate, chitin, chitosan 1, chitosan 2, and derivatives thereof, and mixtures of these glycosaminoglycans or their derivatives,
Claim 28
Dependent Claim
20 words
The composition of claim 19, wherein the collagen is selected from the group consisting of fibrillar collagen or nonfibrillar collagen.
Claim 29
Independent Claim
77 words
A method for preparing a glycosaminoglycan-polymer conjugate suitable for administration to mammals, comprising the steps of: providing an aqueous solution of chemically derivatized glycosaminoglycan; adding a solution of an activated synthetic polymer to form a reaction mixture, wherein said activated polymer comprises a hydrophilic synthetic polymer having a reactive group capable of forming a covalent bond with an available amino group on the chemically derivatized glycosaminoglycan; and causing said polymer to form covalent bonds with the glycosaminoglycan.
Claim 30
Independent Claim
77 words
A method for preparing a glycosaminoglycan-polymer conjugate suitable for administration to mammals, comprising the steps of: providing an aqueous solution of chemically derivatized glycosaminoglycan; adding a solution of an activated synthetic polymer to form a reaction mixture, wherein said activated polymer comprises a hydrophilic synthetic polymer having a reactive group capable of forming a covalent bond with an available amino group on the chemically derivatized glycosaminoglycan; and causing said polymer to form covalent bonds with the glycosaminoglycan.
Claim 31
Dependent Claim
48 words
The method of claim 25, wherein the chemically derivatized glycosaminoglycan is selected from the group consisting of derivatives of the following glycosaminoglycans: hyaluronic acid, chondroitin sulfate A, chondroitin sulfate C, dermatan sulfate, heparin, keratan sulfate, keratosulfate, chitin, chitosan 1, chitosan 2, and mixtures of derivatives of these glycosaminoglycans.
Claim 32
Dependent Claim
16 words
The method of claim 25, wherein the chemically derivatized glycosaminoglycan is derivatized by deacetylation or desulfation.
Claim 33
Dependent Claim
16 words
The method of claim 25, wherein the activated synthetic polymer is a multifunctionally activated polyethylene glycol.
Claim 34
Dependent Claim
16 words
The method of claim 28, wherein the activated synthetic polymer is a difunctionally activated polyethylene glycol.
References Cited (Backward Citations)
US3619371A
Cited
US3788948A
Cited
US3876501A
Cited
US4055635A
Cited
US4179337A
Cited
US3960830A
Cited
US3949073A
Cited
US4088538A
Cited
US4488911A
Cited
US4002531A
Cited
US4192021A
Cited
US4261973A
Cited
US4301144A
Cited
US4378017A
Cited
US4563490A
Cited
US4314380A
Cited
US4415665A
Cited
US4414147A
Cited
US4412989A
Cited
US4451568A
Cited
US4357274A
Cited
US4495285B1
Cited
US4495285A
Cited
US4451397A
Cited
US4424208A
Cited
US4582640A
Cited
EP0098110A2
Cited
US4737544A
Cited
WO1984001106A1
Cited
US4592864A
Cited
US4448718A
Cited
US4496689A
Cited
US4703108A
Cited
US4678468A
Cited
US4687820A
Cited
US4557764A
Cited
US4563350A
Cited
US4935465A
Cited
US4582865A
Cited
US5128326A
Cited
US4689399A
Cited
US4732863A
Cited
US5099013A
Cited
US4642117A
Cited
EP0200574A2
Cited
US4828563A
Cited
US4766106A
Cited
US5202431A
Cited
WO1987004078A1
Cited
EP0247860A2
Cited
US4745180A
Cited
US4979959A
Cited
US5166187A
Cited
JPS643116A
Cited
US4937270A
Cited
US4847325A
Cited
US5137875A
Cited
US5162430A
Cited
US5324775A
Cited
US5201764A
Cited
JPH04227265A
Cited
US5017229A
Cited
EP0466300A2
Cited
USPTO Annuity & Maintenance Windows
| Annuity Stage | Window Opens | Payment Deadline | Surcharge Period Until | Estimated Fee | Status |
|---|---|---|---|---|---|
| 3.5 Years (Year 4) | 1999-04-23 | 1999-10-23 | 2000-04-23 | $2000.00 | Window Closed / Lapsed |
| 7.5 Years (Year 8) | 2003-04-23 | 2003-10-23 | 2004-04-23 | $3760.00 | Window Closed / Lapsed |
| 11.5 Years (Year 12) | 2007-04-23 | 2007-10-23 | 2008-04-23 | $7700.00 | Window Closed / Lapsed |